Comparative Pharmacology
Head-to-head clinical analysis: LORAZEPAM PRESERVATIVE FREE versus TEMAZ.
Head-to-head clinical analysis: LORAZEPAM PRESERVATIVE FREE versus TEMAZ.
LORAZEPAM PRESERVATIVE FREE vs TEMAZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Benzodiazepine that enhances GABA-A receptor activity, increasing chloride ion conductance and producing sedative, anxiolytic, anticonvulsant, and muscle relaxant effects.
Temazepam, a benzodiazepine, enhances the effect of gamma-aminobutyric acid (GABA) at the GABA-A receptor, increasing chloride ion conductance and causing neuronal hyperpolarization, leading to anxiolytic, sedative, and hypnotic effects.
0.5-2 mg orally every 6-8 hours as needed; maximum 4 mg/day. IV: 0.044 mg/kg (max 4 mg) every 6-8 hours for acute anxiety or sedation.
Temazepam 15-30 mg orally at bedtime, up to 60 mg if needed.
None Documented
None Documented
Terminal elimination half-life: 12–14 hours (range 10–20 h). Clinically, no active metabolites; accumulation minimal at standard dosing intervals.
Clinical Note
moderateTemazepam + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Temazepam is combined with Fluticasone propionate."
Clinical Note
moderateTemazepam + Teriflunomide
"The metabolism of Teriflunomide can be decreased when combined with Temazepam."
Clinical Note
moderateTemazepam + Haloperidol
"The risk or severity of adverse effects can be increased when Temazepam is combined with Haloperidol."
Clinical Note
moderateTemazepam + Sulfisoxazole
Terminal elimination half-life: 1.5–2 hours; in severe renal impairment (CrCl <30 mL/min), half-life may extend to 4–6 hours, requiring dose adjustment.
Renal: ~88% as glucuronide conjugates; <1% unchanged. Fecal: ~7%. Biliary: minor.
Renal: ~80% as unchanged drug and metabolites; biliary/fecal: ~20%.
Category D/X
Category C
Benzodiazepine
Benzodiazepine
"The metabolism of Sulfisoxazole can be decreased when combined with Temazepam."